Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2341-2354

  Chan, Stephen ^a   Friedrichs, Kay ^a   Noel, Daniel ^a   Pintér, Tamàs ^a   Van Belle, Simon ^a   Vorobiof, Daniel ^a   Duarte, Ricardo ^a   Gil, Miguel Gil ^a   Bodrogi, Istvan ^a   Murray, Elizabeth ^a   Yelle, Louise ^a   von Minckwitz, Gunter ^a   Korec, Stefan ^a   Simmonds, Peter ^a   Buzzi, Franco ^a   González Mancha, Rosario ^a   Richardson, Gary ^a   Walpole, Euan ^a   Ronzoni, Monica ^a   Murawsky, Michael ^a   Alakl, May ^a   Riva, Alessandro ^a   Crown, John ^a   more..

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; STOMATITIS; VOMITING;

EID: 0032787785     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2341     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
2. Mouridsen HT: Systemic therapy of advanced breast cancer. Drugs 44:17-28, 1992
3. Ingle JN, Maillard JA, Schaid DJ, et al: Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. Am J Clin Oncol 12:474-480, 1989
4. Neidhart JA, Gochnour D, Roach R, et al: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4:672-677, 1986
5. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and Adriamycin in patients with advanced breast cancer: A Southwest Oncology Group study. Cancer 38:13-20, 1976
6. Vaughn CB, Green SJ, O'Bryan R, et al: VP-16 + Adriamycin vs. Adriamycin alone in advanced adenocarcinoma of the breast: Phase II, A randomized trial - A Southwest Oncology Group study. Med Pediatr Oncol 16:312-319, 1988
7. Henderson IC, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:560-571, 1989
8. Hortobagyi GN, Yap HY, Kau SW, et al: A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 12:57-62, 1989
9. Perez DJ, Harvey VJ, Robinson BA, et al: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9:2148-2152, 1991
10. Henderson IC: Chemotherapy for metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, JB Lippincott, 1991, pp 604-665
11. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973
12. Henderson IC, Frei E III: Adriamycin cardiotoxicity. Am Heart J 99:671-674, 1980
13. Unverferth DV, Magorien RD, Leier CV, et al: Doxorubicin cardiotoxicity. Cancer Treat Rev 9:149-164, 1982
14. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
15. Stewart CF, Ratain MJ: Topoisomerase interactive agents, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott-Raven, 1997, pp 452-467
16. van Oosterom AT: Docetaxel (Taxotere): An effective agent in the management of second-line breast cancer. Semin Oncol 22:22-28, 1995 (suppl 13)
17. Fumoleau P, Seidman AD, Trudeau ME, et al: Docetaxel: A new active agent in the therapy of metastatic breast cancer. Exp Opin Invest Drugs 6:1853-1865, 1997
18. Trudeau ME: Docetaxel (Taxotere): An overview of first-line monotherapy. Semin Oncol 22:17-21, 1995 (suppl 13)
19. Riva A, Fumoleau P, Roché H, et al: Efficacy and safety of different corticosteroid premedications in breast cancer patients treated with Taxotere®. Proc Am Soc Clin Oncol 16:188a, 1997 (abstr 660)
20. Schwartz RG, McKenzie WB, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
23. Osoba D, Zee B, Pater J, et al: Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 3:353-364, 1994
24. Collett D: Modelling Survival Data in Medical Research. London, United Kingdom, Chapman and Hall, 1994
25. Jennrich RI, Schluchter MD: Unbalanced repeated-measures models with structured covariance matrices. Biometrics 42:805-820, 1986
26. Schluchter MD: Methods for the analysis of informatively censored longitudinal data. Stat Med 11:1861-1870, 1992
27. Little RJA: Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 90:1112-1121, 1995
28. Muss HB, Case LD, Richards F III, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer: The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
29. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
30. Dixon AR, Jackson L, Chan SY, et al: Continuous chemotherapy in responsive metastatic breast cancer: A role for tumour markers? Br J Cancer 68:181-185, 1993
31. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast cancer. Br J Cancer 56:471-473, 1987
32. Gamucci T, Piccart M, Brüning P, et al: Single agent Taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC): Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17: 111a, 1998 (abstr 428)
33. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)